Skip to main content

Mahmoud Suleiman, MD

Original Contribution
08/01/2008
The development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors has been a major advance in reducing ischemic complications among a broad spectrum of patients undergoing percutaneous coronary intervention (PCI).1–9 Currently, three...
The development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors has been a major advance in reducing ischemic complications among a broad spectrum of patients undergoing percutaneous coronary intervention (PCI).1–9 Currently, three...
The development of platelet...
08/01/2008
Journal of Invasive Cardiology